FDA Signals Shortage For Teva Pharma's ADHD Drug Due To Manufacturing Delay - Teva Pharmaceutical Indus (NYSE:TEVA)


  • The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd TEVA.
  • Adderall is indicated to treat Attention Deficit Hyperactivity Disorder (ADHD). It is an FDA-approved prescription drug made of two stimulants, amphetamine and dextroamphetamine.
  • Other manufacturers continue to produce amphetamine-mixed salts. Still, the FDA said there is insufficient supply to meet U.S. market demand through those producers.
  • According to the FDA’s website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023.
  • “It is possible that some people may encounter a backorder (intermittently) based on timing and high demand, but these are only temporary … and we expect inventory recovery in the coming months,” Teva said.
  • Five doses of Teva’s generic immediate-release Adderall are on backorder, with recovery expected in March, including the most popular 10mg, 20mg, and 30mg pills, according to the FDA. 
  • Most of Teva’s branded immediate-release formulations are available, but the 10mg tablets are also on backorder, with recovery expected this month.
  • Price Action: TEVA shares traded 1.36% higher at $8.18 premarket on the last check Thursday.


Image and article originally from www.benzinga.com. Read the original article here.